Additional file 4 of Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer

Additional file 4 (Fig. S4 Target validation screen using Class I or II selective HDAC inhibitors. a Single drug and combination dose response curves of AZD7762 with either Romidepsin (Class I selective HDAC inhibitor) or Roybinostat (Class II selective inhibitor) across (i) WT and (ii) RR FaDu, with accompanying b Fa-CI (fraction affected-combination index) plot. c Single drug and combination dose response curves of AZD7762 with either Romidepsin or Roybinostat across (i) WT and (ii) RR HK-1, with accompanying d Fa-CI plot. Combination indices of log(CI) <0 across a range of effect sizes (Fa) is indicative of a synergistic interaction. Data presented as means ± SD of two technical replicates.)